Eli Lilly and Company (NYSE:LLY) Stake Raised by Tradewinds LLC.

Tradewinds LLC. raised its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 2.4% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,812 shares of the company’s stock after acquiring an additional 135 shares during the quarter. Eli Lilly and Company makes up 1.6% of Tradewinds LLC.’s investment portfolio, making the stock its 21st largest holding. Tradewinds LLC.’s holdings in Eli Lilly and Company were worth $5,149,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. German American Bancorp Inc. boosted its holdings in shares of Eli Lilly and Company by 1.6% during the third quarter. German American Bancorp Inc. now owns 2,284 shares of the company’s stock worth $2,023,000 after purchasing an additional 36 shares during the period. Trustmark National Bank Trust Department lifted its position in Eli Lilly and Company by 3.6% in the 3rd quarter. Trustmark National Bank Trust Department now owns 3,564 shares of the company’s stock worth $3,157,000 after buying an additional 125 shares in the last quarter. STAR Financial Bank boosted its stake in shares of Eli Lilly and Company by 3.5% during the 3rd quarter. STAR Financial Bank now owns 504 shares of the company’s stock valued at $447,000 after buying an additional 17 shares during the period. Landscape Capital Management L.L.C. purchased a new position in shares of Eli Lilly and Company during the 3rd quarter valued at $1,449,000. Finally, King Luther Capital Management Corp grew its holdings in shares of Eli Lilly and Company by 3.5% during the 3rd quarter. King Luther Capital Management Corp now owns 133,682 shares of the company’s stock valued at $118,434,000 after acquiring an additional 4,501 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have commented on the company. Redburn Atlantic upgraded Eli Lilly and Company to a “hold” rating in a research note on Monday, November 4th. Cantor Fitzgerald restated an “overweight” rating and issued a $885.00 price objective on shares of Eli Lilly and Company in a report on Monday, September 16th. Sanford C. Bernstein began coverage on shares of Eli Lilly and Company in a research note on Thursday, October 17th. They issued an “outperform” rating and a $1,100.00 target price for the company. Wells Fargo & Company boosted their target price on shares of Eli Lilly and Company from $875.00 to $1,000.00 and gave the stock an “overweight” rating in a research report on Friday, August 9th. Finally, Berenberg Bank raised their price target on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a report on Wednesday, August 14th. Four analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $1,007.94.

Insiders Place Their Bets

In related news, CAO Donald A. Zakrowski sold 900 shares of the business’s stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $803.38, for a total value of $723,042.00. Following the completion of the transaction, the chief accounting officer now owns 5,480 shares in the company, valued at $4,402,522.40. The trade was a 14.11 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock opened at $753.41 on Thursday. The stock has a market capitalization of $715.23 billion, a price-to-earnings ratio of 81.45, a P/E/G ratio of 2.76 and a beta of 0.43. The firm’s 50-day moving average price is $872.25 and its two-hundred day moving average price is $869.98. The company has a current ratio of 1.27, a quick ratio of 0.97 and a debt-to-equity ratio of 2.03. Eli Lilly and Company has a 1-year low of $561.65 and a 1-year high of $972.53.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 EPS for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The business had revenue of $11.44 billion for the quarter, compared to the consensus estimate of $12.09 billion. During the same quarter last year, the company earned $0.10 earnings per share. The firm’s revenue was up 20.4% on a year-over-year basis. On average, equities analysts predict that Eli Lilly and Company will post 13.21 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be given a dividend of $1.30 per share. The ex-dividend date of this dividend is Friday, November 15th. This represents a $5.20 annualized dividend and a yield of 0.69%. Eli Lilly and Company’s dividend payout ratio (DPR) is 56.22%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.